Partnerships & Mergers

Verzenios is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Lilly for the treatment of several forms of breast cancer.

The agreement establishes a formal gateway between Abu Dhabi and California, creating new opportunities for collaboration across research, innovation, investment, and commercialization.

Through the HELM Cluster, the emirate has brought together research institutions, advanced healthcare infrastructure, genomics programs, manufacturing capabilities, and distribution networks within a single ecosystem.

The agreement was formalized by Ali El Ghamrawy, Chairperson of the Egyptian Drug Authority, and James Peter Komie, Chairperson of the Pharmacy Board of Sierra Leone, in the presence of Sierra Leone’s Ambassador to Egypt, Sadiq Sillah.

The proposed centre will operate within Abu Dhabi’s Health, Endurance, Longevity, and Medicine (HELM) Cluster, a strategic life sciences platform that integrates research, healthcare delivery, investment, commercialization, and biomanufacturing.

Unlike conventional EHR systems that add AI as an extra feature, IntelliCare places artificial intelligence at the centre of the clinical workflow.

This broader licence gives AviadoBio the flexibility to explore new development pathways and external collaborations while continuing to advance its central nervous system pipeline.

Through the collaboration, the two companies aim to help healthcare providers improve efficiency, streamline operations, and enhance the quality of care delivered to patients.

The African Pooled Procurement Mechanism, led by the Africa Centres for Disease Control and Prevention, is designed to help Member States aggregate demand for medicines, vaccines, diagnostics, and other essential medical supplies.

Under this agreement, CellSave Arabia will act as the exclusive provider of cord blood, cord tissue, placental tissue, cord vessel, and amnion preservation services.